期刊文献+

MDR1基因甲基化与新疆维吾尔族、汉族宫颈癌新辅助化疗疗效的相关性

Methylation of MDR1 gene in promoter region is related with the effect of neoadjuvant chemotherapy on cervical carcinoma in Uigur and Han of Xinjiang
下载PDF
导出
摘要 目的:探讨多药耐药基因(MDR1)启动子区的甲基化状态与新疆维吾尔族、汉族宫颈癌新辅助化疗疗效的相关性。方法:采用MassARRY EpiTYPER DNA甲基化分析技术定量分析宫颈鳞癌61例(汉族:39例,维吾尔族:22例)新辅助化疗前后及正常宫颈组织50例(汉族:30例,维吾尔族:20例)中MDR1基因启动子区22个CpG位点的甲基化状态。结果:(1)宫颈癌组的平均甲基化率均低于正常宫颈组,汉族除了CpG-11,CpG-12、13,CpG-23,CpG-30,维吾尔族除了CpG-5,CpG-11,CpG-12、13,CpG-19、20,CpG-22,CpG-23,CpG-25、26、27外,其余CpG单位差异均有统计学意义(P<0.05)。(2)在维吾尔族、汉族化疗前宫颈癌平均甲基化率比较中发现,CpG-5,CpG-7,CpG-8,CpG-19、20,CpG-23,CpG-25、26、27,差异有统计学意义(P<0.05)。(3)宫颈癌新辅助化疗后的平均甲基化率低于化疗前,汉族CpG-7,CpG-8,CpG-12、13,CpG-18,CpG-23及维吾尔族的CpG-7,CpG-8,CpG-12、13,CpG-18,CpG-19、20,CpG-25、26、27,CpG-30差异有统计学意义(P<0.05)。(4)新辅助化疗耐药组的平均甲基化率低于敏感组,汉族CpG-2、3、4及维吾尔族CpG-6,CpG-7,CpG-8,CpG-12、13,CpG-19、20,CpG-23,CpG-30差异有统计学意义(P<0.05)。结论:MDR1基因启动子区部分CpG岛的异常甲基化与宫颈癌的新辅助化疗疗效密切相关,且在维吾尔族、汉族之间存在一定差异。 Objective:To investigate the correlation between methylation of MDR1 gene in promoter region and the effect of neoadjuvant chemotherapy on cervical carcinoma in Uigur and Han of xinjiang.Method:Mass ARRY EpiTYPER DNA methylation analyzing technique was used to detect the 22 CPG sites methylation status of MDR1 gene promoter region which in groups before and after NACT of cervical carcinoma and normal group.Results:(1)The average methylation rate in cervical carcinoma group was lower than that in the normal group,except CpG-11,CpG-12,13,CpG-23,CpG-30 of Han and CpG-5,CpG-11,CpG-12,13,CpG-19,20,CpG-22,CpG-23,CpG-25,26,27 of Uigur(P0.05).(2)We found the average methylation rate of CpG-5,CpG-7,CpG-8,CpG-19,20,CpG-23,CpG-25,26,27 have significant difference in Uigur and Han in before NACT group(P0.05).(3)The average methylation rate in after NACT group was lower than that in before NACT group,CpG-7,CpG-8,CpG-12,13,CpG-18,CpG-23 of Han and CpG-7,CpG-8,CpG-12,13,CpG-18,CpG-19,20,CpG-25,26,27,CpG-30 of Uigur significant difference were found(P0.05).(4)The average methylation rate in drug resistance group was lower than that in sensitive group,CpG-2,3,4 of Han and CpG-6,CpG-7,CpG-8,CpG-12,13 CpG-19,20 CpG-23 CpG-30 of Uigur significant difference was found(P0.05).Conclusion:There is closely correlation between parts CPG island abnormal methylation of MDR1 gene in promoter region and the effect of neoadjuvant chemotherapy on cervical carcinoma,and some differences were also found in Uigur and Han.
出处 《现代妇产科进展》 CSCD 北大核心 2011年第8期604-609,共6页 Progress in Obstetrics and Gynecology
基金 石河子大学重大攻关专项基金项目(No:gxji2008-zdgg07)
关键词 MDR1基因 甲基化 宫颈癌 新辅助化疗 维吾尔族 汉族 MDR1 gene Methylation Cervical carcinoma Neoadjuvant chemotherapy Uigur Han
  • 相关文献

参考文献7

  • 1Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and over ex- pression of the human mdrl gene in acute myeloid leuke- mias [ J ]. Blood, 1998,92 ( 11 ) :4296-4307.
  • 2Chen G, Duran GE, Steger KA, et al. Multi-drug-resistant human sarcoma tens with a mutant P-glycopmtein, altered phenotype,and resistanceto eyelosporim [ J ]. Biol Chem, 1997,272(9) :5974-5982.
  • 3Gonzalgo ML, Hayashida T, Bender CM, et al. The role of DNA methylation in expression of the p19/p16 local in human bladder cancer cell lines [ J]. Cancer, 1998,58 (6) : 1245-1252.
  • 4Baker EK, El-Osta A. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer[ J]. Exp Cell RES,2003,290(2) : 177-194.
  • 5Kass SU, Landsberger N, Wolffe AP, et al. DNA methyla- tion directs a time dependent repression of transcription [J]. Curt Bid,1997,7(3) :157-165.
  • 6Honjo Y, Hrycyna CA, Yan QW, et al. Acquiredmutations in the MxR/BCRP/AbcP geneaher substrate specificity in MXR/BCRP, ABCP-overexpressing cells [ J ]. Cancer Res, 2001,61:6635-6639.
  • 7朱燕,武淑兰,卜定方,李渊,朱强,曹香红.恶性血液病患者mdr1基因启动子区甲基化状态及其与表达的关系[J].中国实验血液学杂志,2004,12(1):6-10. 被引量:6

二级参考文献10

  • 1[1]Ogretmen B, Safa AR. Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line. Biochemistry, 2000; 39:194-204
  • 2[2]Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood, 2002; 100: 1233-1239
  • 3[3]Kusaba H, Nakayarna M, Harada T, et al. Maintenance of hypomethylation status and preferential expression of exogenous human MDR1/PGY1 gene in mouse L cells by YAC mediated transfer. Somat Cell Mol Genet, 1997; 23:259- 274
  • 4[4]Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood, 1998; 92: 42964307
  • 5[5]Tada Y, Wada M, Kuroiwa K, et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer res, 2000;6:4618-4627
  • 6[6]Toyota M, Kopecky KJ, Toyota MO, et al. Methylation profiling in acute myeloid leukemia. Blood, 2001; 97:2823- 2829
  • 7[7]Garcia-Manero G, Bueso-Ramos C, Daniel J, et al. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res,2002; 8:1897 - 1903
  • 8[8]Fryxell KB, McGee SB, Simoneaux DK, et al. Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells. Leukemia, 1999; 13:910-917
  • 9[9]Ando T, Nishimura M, Oka Y. Decitabine (5-Aza-2-deoxycyti dine) decreased DNA methylation and expression of MDRl gene in K562/ADM cells. Leukemia, 2000; 14:1915-1920
  • 10[10]Cornwell MM, Smith DE. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem, 1993; 268:19505-19511

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部